Skip to main content
. 2014 Mar;88(5):2927–2940. doi: 10.1128/JVI.03406-13

FIG 4.

FIG 4

BAY11 or knockdown of RELA/p65 reverses vorinostat or MS-275-mediated enhancement of VSV oncolysis. (A and B) PC3 cells were pretreated with DMSO (black bars), MS-275 (2 μM) (dark-gray bars), or vorinostat (5 μM) (light-gray bars) with or without BAY11 (10 μM) and infected with VSV-GFP (MOI = 0.01), as indicated below the graphs, for 24 h. Viral replication was quantified by flow cytometry (A) or plaque assay (B). (C) Cell viability of PC3 cells was measured by flow cytometry as a percentage of GFP and annexin V double-negative cells. (D and E) Quantification of VSV replication by immunoblotting (D) or plaque assay (E) in Ctrl-Luc (white bars) and shRel (black bars) cells exposed to VSV with or without vorinostat. (F) Quantification of VSV genomic mRNA by qPCR in Luc-Ctrl (white bars) and shRel (black bars) cells exposed to VSV with or without vorinostat at 12 and 24 h postinfection. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.005. The error bars indicate SD.